MA37324A1 - Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie - Google Patents

Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie

Info

Publication number
MA37324A1
MA37324A1 MA37324A MA37324A MA37324A1 MA 37324 A1 MA37324 A1 MA 37324A1 MA 37324 A MA37324 A MA 37324A MA 37324 A MA37324 A MA 37324A MA 37324 A1 MA37324 A1 MA 37324A1
Authority
MA
Morocco
Prior art keywords
enuresis
treatment
pharmaceutical composition
proportion
composition
Prior art date
Application number
MA37324A
Other languages
English (en)
French (fr)
Inventor
Agustí Juan Carlos Llobregat
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of MA37324A1 publication Critical patent/MA37324A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA37324A 2012-02-15 2013-01-22 Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie MA37324A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
PCT/ES2013/070022 WO2013121061A1 (es) 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Publications (1)

Publication Number Publication Date
MA37324A1 true MA37324A1 (fr) 2016-03-31

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37324A MA37324A1 (fr) 2012-02-15 2013-01-22 Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie

Country Status (20)

Country Link
US (1) US9272011B2 (enExample)
EP (1) EP2815755A4 (enExample)
JP (1) JP6203761B2 (enExample)
KR (1) KR20140127874A (enExample)
CN (1) CN104254338B (enExample)
AU (1) AU2013220284A1 (enExample)
BR (1) BR112014020154A8 (enExample)
CA (1) CA2864426A1 (enExample)
CL (1) CL2014002128A1 (enExample)
CO (1) CO7141408A2 (enExample)
CR (1) CR20140419A (enExample)
EA (1) EA028184B1 (enExample)
ES (1) ES2423254B1 (enExample)
IL (1) IL233978A0 (enExample)
MA (1) MA37324A1 (enExample)
MX (1) MX367671B (enExample)
PE (1) PE20142324A1 (enExample)
PH (1) PH12014501823A1 (enExample)
WO (1) WO2013121061A1 (enExample)
ZA (1) ZA201406668B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
AU677008B2 (en) 1992-05-20 1997-04-10 Northwestern University Gaba and L-glutamic acid analogs for antiseizure treatment
AU779262B2 (en) * 1999-04-08 2005-01-13 Warner-Lambert Company Method for the treatment of incontinence
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
ZA200601975B (en) * 2003-09-11 2007-05-30 Xenoport Inc Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
JP4815558B2 (ja) * 2003-10-09 2011-11-16 パシフィック アロー リミテッド Ｘａｎｔｈｏｃｅｒａｓｓｏｒｂｉｆｏｌｉａ抽出物を含む組成物、該抽出物から単離された化合物、それらを調製する方法、およびそれらの使用
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
IL233978A0 (en) 2014-09-30
EP2815755A1 (en) 2014-12-24
WO2013121061A1 (es) 2013-08-22
CO7141408A2 (es) 2014-12-12
CN104254338B (zh) 2019-05-31
CN104254338A (zh) 2014-12-31
ES2423254A1 (es) 2013-09-18
CL2014002128A1 (es) 2015-03-13
US20150044308A1 (en) 2015-02-12
EA201491437A1 (ru) 2015-06-30
EP2815755A4 (en) 2015-08-05
BR112014020154A2 (enExample) 2017-06-20
MX367671B (es) 2019-08-30
US9272011B2 (en) 2016-03-01
EA028184B1 (ru) 2017-10-31
JP6203761B2 (ja) 2017-09-27
PE20142324A1 (es) 2015-01-16
CR20140419A (es) 2014-11-28
KR20140127874A (ko) 2014-11-04
AU2013220284A1 (en) 2014-09-25
BR112014020154A8 (pt) 2017-07-11
ES2423254B1 (es) 2014-03-26
PH12014501823A1 (en) 2014-11-24
JP2015507002A (ja) 2015-03-05
ZA201406668B (en) 2016-05-25
MX2014009464A (es) 2014-11-12
CA2864426A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
Isaacs et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
CA2963208C (en) Use of cannabinoids in the treatment of epilepsy
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
Quintanilla et al. Intranasal mesenchymal stem cell secretome administration markedly inhibits alcohol and nicotine self-administration and blocks relapse-intake: mechanism and translational options
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
WO2002069993A8 (de) Cannabis extrakten pharmazeutische zusammensetzung
MA33449B1 (fr) Antigènes recombinants du vrs
WO2007120883A3 (en) Compositions and their uses directed to hepcidin
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
Mohana et al. Inhibition of differentiation of monocyte to macrophages in atherosclerosis by oligomeric proanthocyanidins–In-vivo and in-vitro study
MA30041B1 (fr) Immunoglobulines
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
MA34308B1 (fr) Triazolopyridines substituées
Wu et al. Effects of epigallocatechin-3-gallate and acyclovir on herpes simplex virus type 1 infection in oral epithelial cells
Yousuf et al. Protective activity of gallic acid against glyoxal-induced renal fibrosis in experimental rats
EP2438923A4 (en) COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF OBSERVATION-BASED ILLNESSES BY THE ACTIVATION OF AMPK AND WITH 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURANLIGNANES AS ACTIVE SUBSTANCES
Pei et al. Response of human periodontal ligament cells to baicalin
Shwetank et al. Infection of human endothelial cells by Japanese encephalitis virus: increased expression and release of soluble HLA-E
Lee et al. Anti-inflammatory effects of bamboo salt and sodium fluoride in human gingival fibroblasts–An in vitro study
Kim et al. Naringenin stimulates osteogenic/odontogenic differentiation and migration of human dental pulp stem cells